HCG and derivatives as matrix metalloproteases inhibitors
AssigneeApplied Research Systems ARS Holding N.V.
InventorsAdriana Albini, Giorgia Orengo
Life of this patent
Estimating the term…
Abstract
The use of hCG, hCG β-subunit, as well as fragments and active derivatives thereof, or hCG β-core in the preparation of a medicament for the prophylaxis and/or the treatment of pathologies requiring inhibition of the matrix metalloprotease (MMP) enzymatic activity.
Claims4
A method for treatment of a pathology requiring inhibition of matrix metalloprotease enzymatic activity selected from the group consisting of chronic inflammatory diseases, multiple schlerosis, and angiogenesis-dependent diseases with the proviso that the pathology is not a tumor or cancer, comprising administering to a subject in need thereof one or more pharmaceutically acceptable excipients and an effective amount of recombinant heterodimeric human chorionic gonadotropin (rhCG).
Dependencies are inferred from the claim text.